Lung Cancer News

The FDA approved FoundationOne Liquid CDx, a comprehensive pan-tumor liquid biopsy test.

The FDA granted priority review to tepotinib for the treatment of certain patients with non-small cell lung cancer, according to the agent’s manufacturer.

The successful completion of active treatment is an important milestone for anyone who has lived with cancer. However, being cancer-free does not always bring the peace of mind patients might expect.

Past trends of higher lung cancer incidence among young Black people vs. young white people have disappeared for men and reversed for women in the United States, according to retrospective study results published in JNCI Cancer Spectrum.

The FDA granted priority review to trilaciclib for treatment of patients with small cell lung cancer who are receiving chemotherapy, according to the agent’s manufacturer.

The addition of sintilimab to pemetrexed and platinum chemotherapy conferred a significant PFS benefit for a subset of patients with nonsquamous non-small cell lung cancer, according to results of an interim analysis of the ORIENT-11 study.

Non-small cell lung cancer mortality decreased substantially among the general U.S. population between 2013 and 2016, according to results of a retrospective study published in The New England Journal of Medicine.

Ensartinib significantly increased PFS compared with crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer, according to an interim analysis of the phase 3, open-label eXalt3 study.

First-line nivolumab plus ipilimumab significantly extended OS compared with platinum-based chemotherapy for patients with unresectable malignant pleural mesothelioma, according to results of an interim analysis of the CheckMate 743 trial.

Black adults with screen-detected cancers had a lower calculated 6-year lung cancer risk compared with white adults, despite a significantly higher mean lung cancer risk, according to new research.